Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors

Cardio-Oncology
Neha BansalSteven E Lipshultz

Abstract

Cancer diagnostics and therapies have improved steadily over the last few decades, markedly increasing life expectancy for patients at all ages. However, conventional and newer anti-neoplastic therapies can cause short- and long-term cardiotoxicity. The clinical implications of this cardiotoxicity become more important with the increasing use of cardiotoxic drugs. The implications are especially serious among patients predisposed to adverse cardiac effects, such as youth, the elderly, those with cardiovascular comorbidities, and those receiving additional chemotherapies or thoracic radiation. However, the optimal strategy for preventing and managing chemotherapy-induced cardiotoxicity remains unknown. The routine use of neurohormonal antagonists for cardioprotection is not currently justified, given the marginal benefits and associated adverse events, particularly with long-term use. The only United States Food and Drug Administration and European Medicines Agency approved treatment for preventing anthracycline-related cardiomyopathy is dexrazoxane. We advocate administering dexrazoxane during cancer treatment to limit the cardiotoxic effects of anthracycline chemotherapy.

References

Oct 11, 1992·Teratology·R A MartinK Benirschke
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H WexlerM E Horowitz
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P KrischerS E Lipshultz
Sep 26, 2000·Molecular Genetics and Metabolism·M S HorensteinT J L'Ecuyer
Nov 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E LipshultzSteven D Colan
Sep 19, 2003·Lancet·Marc A PfefferUNKNOWN CHARM Investigators and Committees
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E Lipshultz, Steven D Colan
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey H SilberHuaqing Zhao
Jul 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Jacob AdamsSteven E Lipshultz
Nov 19, 2004·Fundamental & Clinical Pharmacology·Lionel ThomasLaurent Monassier
May 26, 2005·JAMA : the Journal of the American Medical Association·Michelle D HolmesGraham A Colditz
Jul 26, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Daniel BernsteinBrian K Kobilka
Dec 13, 2006·Journal of the American College of Cardiology·Nihat KalayAli Ergin
Feb 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cameron K TebbiCindy L Schwartz
Jul 27, 2007·Cardiovascular Toxicology·Brian B Hasinoff, Eugene H Herman
Mar 19, 2008·Heart·Steven E LipshultzRebecca E Scully
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca GianniDouglas B Sawyer
Aug 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grace L SmithDavid I Rosenthal
Feb 2, 2010·Journal of the American College of Cardiology·Daniela CardinaleCarlo M Cipolla
Feb 2, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M C Cardous-UbbinkF E Van Leeuwen
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E Lipshultz, M Jacob Adams
Feb 16, 2010·The American Journal of Cardiology·John RickardBruce L Wilkoff
Jun 19, 2010·Medicine and Science in Sports and Exercise·Kathryn H SchmitzUNKNOWN American College of Sports Medicine
Jul 22, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Tracie L MillerSteven E Lipshultz
Sep 3, 2010·Journal of Korean Medical Science·Hyoung Soo ChoiJung Yun Choi
Apr 26, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lynda M VroomanStephen E Sallan
Aug 5, 2011·Journal of the National Cancer Institute·Thomas P AhernTimothy L Lash
Aug 20, 2011·Journal of the American College of Cardiology·Zeydin AcarMustafa Tarık Ağaç

❮ Previous
Next ❯

Citations

Sep 24, 2020·Journal of Biomolecular Structure & Dynamics·Ibrahim MalamiImaobong C Etti
Feb 7, 2020·Cancer Metastasis Reviews·Neha BansalSteven E Lipshultz
Apr 1, 2020·Frontiers in Cardiovascular Medicine·Alessandra MurabitoAlessandra Ghigo
Aug 11, 2020·Expert Opinion on Drug Metabolism & Toxicology·Kateryna PetrykeyMaja Krajinovic
Feb 9, 2021·World Journal of Cardiology·Esther G ChongChung-Tsen Hsueh
Nov 15, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Raluca Maria PopAda Popolo
Aug 3, 2021·Experimental and Therapeutic Medicine·Bingpeng DengYong Wang
Aug 28, 2021·Biomolecules·Alberto Fernández-MedardeEugenio Santos

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01988571
NCT02164721

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.